Insider Selling: Zimmer Biomet Holdings Inc (NYSE:ZBH) Insider Sells 147 Shares of Stock

Zimmer Biomet Holdings Inc (NYSE:ZBH) insider Sang Yi sold 147 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $138.70, for a total value of $20,388.90. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Sang Yi also recently made the following trade(s):

  • On Friday, May 24th, Sang Yi sold 426 shares of Zimmer Biomet stock. The shares were sold at an average price of $114.88, for a total value of $48,938.88.

ZBH traded down $0.62 on Friday, hitting $138.31. The company had a trading volume of 880,902 shares, compared to its average volume of 1,257,010. The firm has a market cap of $27.75 billion, a P/E ratio of 18.10, a PEG ratio of 2.42 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 12-month low of $96.99 and a 12-month high of $139.71. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.56 and a current ratio of 1.19. The company’s fifty day moving average is $124.39.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Friday, July 26th. The medical equipment provider reported $1.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.91 by $0.02. The company had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.98 billion. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. The firm’s revenue was down .9% on a year-over-year basis. During the same quarter last year, the business posted $1.92 earnings per share. On average, sell-side analysts anticipate that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 31st. Investors of record on Friday, June 28th were given a $0.24 dividend. The ex-dividend date of this dividend was Thursday, June 27th. This represents a $0.96 annualized dividend and a yield of 0.69%. Zimmer Biomet’s dividend payout ratio is currently 12.57%.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its position in shares of Zimmer Biomet by 5.5% during the first quarter. Nisa Investment Advisors LLC now owns 85,539 shares of the medical equipment provider’s stock valued at $10,923,000 after buying an additional 4,496 shares during the period. Hartford Investment Management Co. boosted its position in shares of Zimmer Biomet by 0.7% during the second quarter. Hartford Investment Management Co. now owns 28,711 shares of the medical equipment provider’s stock valued at $3,380,000 after buying an additional 208 shares during the period. LaFleur & Godfrey LLC raised its stake in shares of Zimmer Biomet by 8.8% during the first quarter. LaFleur & Godfrey LLC now owns 36,320 shares of the medical equipment provider’s stock valued at $4,638,000 after acquiring an additional 2,935 shares in the last quarter. GAM Holding AG raised its stake in shares of Zimmer Biomet by 17.1% during the first quarter. GAM Holding AG now owns 18,791 shares of the medical equipment provider’s stock valued at $2,400,000 after acquiring an additional 2,748 shares in the last quarter. Finally, Israel Discount Bank of New York raised its stake in shares of Zimmer Biomet by 3.9% during the first quarter. Israel Discount Bank of New York now owns 7,079 shares of the medical equipment provider’s stock valued at $904,000 after acquiring an additional 266 shares in the last quarter. Institutional investors own 88.57% of the company’s stock.

A number of research firms have commented on ZBH. Cowen set a $140.00 price target on Zimmer Biomet and gave the company a “hold” rating in a report on Friday, July 26th. Robert W. Baird raised Zimmer Biomet from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $132.00 to $154.00 in a report on Monday, July 29th. Raymond James lifted their target price on Zimmer Biomet from $145.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, July 29th. Cantor Fitzgerald set a $135.00 target price on Zimmer Biomet and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, Needham & Company LLC raised Zimmer Biomet from a “buy” rating to a “strong-buy” rating and lifted their target price for the stock from $146.00 to $155.00 in a report on Wednesday, April 24th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Zimmer Biomet has an average rating of “Buy” and a consensus price target of $140.64.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Story: What is a Derivative?

Insider Buying and Selling by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.